Skip to main content
Erschienen in: Inflammation 6/2015

01.12.2015

Methyl-CpG-Binding Protein 2 (MECP2) Polymorphism in Iranian Patients with Systemic Lupus Erythematosus

verfasst von: Samira Alesaeidi, Jafar Karami, Mahdi Mahmoudi, Mahmoud Akbarian, Shiva Poursani, Azadeh Amirzadeh, Nazgol-Sadat Haddadi, Elahe Saffari, Ahmad Reza Jamshidi

Erschienen in: Inflammation | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease which involves many organs and presents with various symptoms. It has been shown that genetic and environmental factors play a major role in this disease and may affect the onset, activity, damage, and mortality of the disease. According to recent studies, methyl-CpG-binding protein 2 (MECP2) has been associated with SLE in various populations. Herein, we studied MECP2 polymorphism in Iranian lupus patients and controls. The study included a total of 884 samples of Iranian ancestry (492 independent SLE patients and 392 unrelated healthy controls). Healthy controls were gender-, ethnic-, and age-matched with the patients. Patient and control samples were genotyped for rs1734787, rs1734791, rs1734792, and rs17435 by applying the Allelic Discrimination Real-Time PCR System. Our results showed a significant association between rs1734787 and rs1734791 SNPs and the risk of SLE in the Iranian population (p = 0.028, p = 0.028), but did not show any significant association with rs1734792 and rs17435 SNPs (p = 075, p = 0.75). The rs1734787 C and the rs1734791 T allele frequencies in the patients were significantly higher than the control group (p = 0.014, p = 0.012). In addition, a significant CTAT haplotype frequency was observed in cases with SLE (p = 0.012), and a significant AAAT haplotype frequency was observed in the control group (p = 0.0003). However, there was no significant association between genotype frequencies and SLE patients. Also, there was no significant association between these SNPs and clinical features. The result of this study suggests that polymorphism in the MECP2 locus is associated with the susceptibility of Iranian SLE patients.
Literatur
1.
2.
4.
Zurück zum Zitat Rahman, A. 2004. Autoantibodies, lupus and the science of sabotage. Rheumatology 43: 1326–1336.CrossRefPubMed Rahman, A. 2004. Autoantibodies, lupus and the science of sabotage. Rheumatology 43: 1326–1336.CrossRefPubMed
5.
Zurück zum Zitat Sawalha, A.H., R. Webb, S. Han, J.A. Kelly, K.M. Kaufman, R.P. Kimberly, M.E. Alarcon-Riquelme, J.A. James, T.J. Vyse, and G.S. Gilkeson. 2008. Common variants within MECP2 confer risk of systemic lupus erythematosus. PloS One 3: e1727.PubMedCentralCrossRefPubMed Sawalha, A.H., R. Webb, S. Han, J.A. Kelly, K.M. Kaufman, R.P. Kimberly, M.E. Alarcon-Riquelme, J.A. James, T.J. Vyse, and G.S. Gilkeson. 2008. Common variants within MECP2 confer risk of systemic lupus erythematosus. PloS One 3: e1727.PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Martens, H., I. Nolte, G. Van der Steege, M. Schipper, C. Kallenberg, G. Te Meerman, and M. Bijl. 2009. An extensive screen of the HLA region reveals an independent association of HLA class I and class II with susceptibility for systemic lupus erythematosus. Scandinavian Journal of Rheumatology 38: 256–262.CrossRefPubMed Martens, H., I. Nolte, G. Van der Steege, M. Schipper, C. Kallenberg, G. Te Meerman, and M. Bijl. 2009. An extensive screen of the HLA region reveals an independent association of HLA class I and class II with susceptibility for systemic lupus erythematosus. Scandinavian Journal of Rheumatology 38: 256–262.CrossRefPubMed
7.
Zurück zum Zitat Yang, W., P. Ng, M. Zhao, N. Hirankarn, C.S. Lau, C.C. Mok, T.-M. Chan, R. Wong, K.W. Lee, and M.Y. Mok. 2009. Population differences in SLE susceptibility genes: STAT4 and BLK, but not PXK, are associated with systemic lupus erythematosus in Hong Kong Chinese. Genes and Immunity 10: 219–226.CrossRefPubMed Yang, W., P. Ng, M. Zhao, N. Hirankarn, C.S. Lau, C.C. Mok, T.-M. Chan, R. Wong, K.W. Lee, and M.Y. Mok. 2009. Population differences in SLE susceptibility genes: STAT4 and BLK, but not PXK, are associated with systemic lupus erythematosus in Hong Kong Chinese. Genes and Immunity 10: 219–226.CrossRefPubMed
8.
Zurück zum Zitat Rhodes, B., and T. Vyse. 2008. The genetics of SLE: an update in the light of genome-wide association studies. Rheumatology 47: 1603–1611.CrossRefPubMed Rhodes, B., and T. Vyse. 2008. The genetics of SLE: an update in the light of genome-wide association studies. Rheumatology 47: 1603–1611.CrossRefPubMed
9.
Zurück zum Zitat Koelsch, K.A., R. Webb, M. Jeffries, M.G. Dozmorov, M.B. Frank, J.M. Guthridge, J.A. James, J.D. Wren, and A.H. Sawalha. 2013. Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse. Journal of Autoimmunity 41: 168–174.PubMedCentralCrossRefPubMed Koelsch, K.A., R. Webb, M. Jeffries, M.G. Dozmorov, M.B. Frank, J.M. Guthridge, J.A. James, J.D. Wren, and A.H. Sawalha. 2013. Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse. Journal of Autoimmunity 41: 168–174.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Alonso-Perez, E., M. Suarez-Gestal, M. Calaza, J. Ordi-Ros, E. Balada, M. Bijl, C. Papasteriades, P. Carreira, F.N. Skopouli, and T. Witte. 2012. Further evidence of subphenotype association with systemic lupus erythematosus susceptibility loci: a European cases only study. PloS One 7: e45356.PubMedCentralCrossRefPubMed Alonso-Perez, E., M. Suarez-Gestal, M. Calaza, J. Ordi-Ros, E. Balada, M. Bijl, C. Papasteriades, P. Carreira, F.N. Skopouli, and T. Witte. 2012. Further evidence of subphenotype association with systemic lupus erythematosus susceptibility loci: a European cases only study. PloS One 7: e45356.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Webb, R., J.D. Wren, M. Jeffries, J.A. Kelly, K.M. Kaufman, Y. Tang, M.B. Frank, J. Merrill, R.P. Kimberly, and J.C. Edberg. 2009. Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis and Rheumatism 60: 1076–1084.PubMedCentralCrossRefPubMed Webb, R., J.D. Wren, M. Jeffries, J.A. Kelly, K.M. Kaufman, Y. Tang, M.B. Frank, J. Merrill, R.P. Kimberly, and J.C. Edberg. 2009. Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis and Rheumatism 60: 1076–1084.PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Mirkazemi, S., M. Akbarian, A.R. Jamshidi, R. Mansouri, S. Ghoroghi, Y. Salimi, Z. Tahmasebi, and M. Mahmoudi. 2013. Association of STAT4 rs7574865 with susceptibility to systemic lupus erythematosus in Iranian population. Inflammation 36: 1548–1552.CrossRefPubMed Mirkazemi, S., M. Akbarian, A.R. Jamshidi, R. Mansouri, S. Ghoroghi, Y. Salimi, Z. Tahmasebi, and M. Mahmoudi. 2013. Association of STAT4 rs7574865 with susceptibility to systemic lupus erythematosus in Iranian population. Inflammation 36: 1548–1552.CrossRefPubMed
13.
Zurück zum Zitat Roe, B. A., J. Crabtree, and A. Khan. 1995. Methods for DNA isolation. Part III. Protocols for recombinant DNA isolation, cloning, and sequencing [Internet edition]. Norman, OK: University of Oklahoma: 2488–2498. Roe, B. A., J. Crabtree, and A. Khan. 1995. Methods for DNA isolation. Part III. Protocols for recombinant DNA isolation, cloning, and sequencing [Internet edition]. Norman, OK: University of Oklahoma: 2488–2498.
14.
Zurück zum Zitat Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological): 289–300. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological): 289–300.
15.
Zurück zum Zitat Yong, Y., and H. Lin. 2005. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Research 15: 97–98.CrossRef Yong, Y., and H. Lin. 2005. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Research 15: 97–98.CrossRef
16.
Zurück zum Zitat Crispín, J.C., S.-N.C. Liossis, K. Kis-Toth, L.A. Lieberman, V.C. Kyttaris, Y.-T. Juang, and G.C. Tsokos. 2010. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends in Molecular Medicine 16: 47–57.PubMedCentralCrossRefPubMed Crispín, J.C., S.-N.C. Liossis, K. Kis-Toth, L.A. Lieberman, V.C. Kyttaris, Y.-T. Juang, and G.C. Tsokos. 2010. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends in Molecular Medicine 16: 47–57.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Jakes, R.W., S.C. Bae, W. Louthrenoo, C.C. Mok, S.V. Navarra, and N. Kwon. 2012. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care & Research 64: 159–168.CrossRef Jakes, R.W., S.C. Bae, W. Louthrenoo, C.C. Mok, S.V. Navarra, and N. Kwon. 2012. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care & Research 64: 159–168.CrossRef
18.
Zurück zum Zitat Pons-Estel, G. J., G. S. Alarcón, L. Scofield, L. Reinlib, and G. S. Cooper. 2010. Understanding the epidemiology and progression of systemic lupus erythematosus. In Seminars in Arthritis and Rheumatism. Elsevier. 257–268 Pons-Estel, G. J., G. S. Alarcón, L. Scofield, L. Reinlib, and G. S. Cooper. 2010. Understanding the epidemiology and progression of systemic lupus erythematosus. In Seminars in Arthritis and Rheumatism. Elsevier. 257–268
19.
Zurück zum Zitat Connelly, K., E. Morand, and A. Hoi. 2013. Asian ethnicity in systemic lupus erythematosus: an Australian perspective. Internal Medicine Journal 43: 618–624.CrossRefPubMed Connelly, K., E. Morand, and A. Hoi. 2013. Asian ethnicity in systemic lupus erythematosus: an Australian perspective. Internal Medicine Journal 43: 618–624.CrossRefPubMed
20.
Zurück zum Zitat Askanase, A., K. Shum, and H. Mitnick. 2012. Systemic lupus erythematosus: an overview. Social Work in Health Care 51: 576–586.CrossRefPubMed Askanase, A., K. Shum, and H. Mitnick. 2012. Systemic lupus erythematosus: an overview. Social Work in Health Care 51: 576–586.CrossRefPubMed
21.
Zurück zum Zitat Moser, K.L., J.A. Kelly, C.J. Lessard, and J.B. Harley. 2009. Recent insights into the genetic basis of systemic lupus erythematosus. Genes and Immunity 10: 373–379.PubMedCentralCrossRefPubMed Moser, K.L., J.A. Kelly, C.J. Lessard, and J.B. Harley. 2009. Recent insights into the genetic basis of systemic lupus erythematosus. Genes and Immunity 10: 373–379.PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Kaufman, K. M., J. Zhao, J. A. Kelly, T. Hughes, A. Adler, E. Sanchez, J. O. Ojwang, C. D. Langefeld, J. T. Ziegler, and A. H. Williams. 2012. Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Annals of the rheumatic diseases: annrheumdis-2012-201851. Kaufman, K. M., J. Zhao, J. A. Kelly, T. Hughes, A. Adler, E. Sanchez, J. O. Ojwang, C. D. Langefeld, J. T. Ziegler, and A. H. Williams. 2012. Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Annals of the rheumatic diseases: annrheumdis-2012-201851.
23.
Zurück zum Zitat Singh, J., A. Saxena, J. Christodoulou, and D. Ravine. 2008. MECP2 genomic structure and function: insights from ENCODE. Nucleic Acids Research 36: 6035–6047.PubMedCentralCrossRefPubMed Singh, J., A. Saxena, J. Christodoulou, and D. Ravine. 2008. MECP2 genomic structure and function: insights from ENCODE. Nucleic Acids Research 36: 6035–6047.PubMedCentralCrossRefPubMed
24.
Zurück zum Zitat Mnatzakanian, G.N., H. Lohi, I. Munteanu, S.E. Alfred, T. Yamada, P.J. MacLeod, J.R. Jones, S.W. Scherer, N.C. Schanen, and M.J. Friez. 2004. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nature Genetics 36: 339–341.CrossRefPubMed Mnatzakanian, G.N., H. Lohi, I. Munteanu, S.E. Alfred, T. Yamada, P.J. MacLeod, J.R. Jones, S.W. Scherer, N.C. Schanen, and M.J. Friez. 2004. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nature Genetics 36: 339–341.CrossRefPubMed
25.
Zurück zum Zitat Kriaucionis, S., and A. Bird. 2004. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Research 32: 1818–1823.PubMedCentralCrossRefPubMed Kriaucionis, S., and A. Bird. 2004. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Research 32: 1818–1823.PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Lewis, J.D., R.R. Meehan, W.J. Henzel, I. Maurer-Fogy, P. Jeppesen, F. Klein, and A. Bird. 1992. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69: 905–914.CrossRefPubMed Lewis, J.D., R.R. Meehan, W.J. Henzel, I. Maurer-Fogy, P. Jeppesen, F. Klein, and A. Bird. 1992. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69: 905–914.CrossRefPubMed
27.
Zurück zum Zitat Meehan, R., J.D. Lewis, and A.P. Bird. 1992. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Research 20: 5085–5092.PubMedCentralCrossRefPubMed Meehan, R., J.D. Lewis, and A.P. Bird. 1992. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Research 20: 5085–5092.PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Nan, X., R.R. Meehan, and A. Bird. 1993. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Research 21: 4886–4892.PubMedCentralCrossRefPubMed Nan, X., R.R. Meehan, and A. Bird. 1993. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Research 21: 4886–4892.PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Damen, D., and R. Heumann. 2013. MeCP2 phosphorylation in the brain: from transcription to behavior. Biological Chemistry 394: 1595–1605.CrossRefPubMed Damen, D., and R. Heumann. 2013. MeCP2 phosphorylation in the brain: from transcription to behavior. Biological Chemistry 394: 1595–1605.CrossRefPubMed
Metadaten
Titel
Methyl-CpG-Binding Protein 2 (MECP2) Polymorphism in Iranian Patients with Systemic Lupus Erythematosus
verfasst von
Samira Alesaeidi
Jafar Karami
Mahdi Mahmoudi
Mahmoud Akbarian
Shiva Poursani
Azadeh Amirzadeh
Nazgol-Sadat Haddadi
Elahe Saffari
Ahmad Reza Jamshidi
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 6/2015
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-015-0201-6

Weitere Artikel der Ausgabe 6/2015

Inflammation 6/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.